Fidelity Disruptive Medicine ETF
FMED
7 hedge funds and large institutions have $34.6M invested in Fidelity Disruptive Medicine ETF in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
11% more capital invested
Capital invested by funds: $31.1M → $34.6M (+$3.53M)
3.5% more ownership
Funds ownership: 62.13% → 65.63% (+3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.22M |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$1.79M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.07M |
FMED Hedge Fund Activity: Q2 2025 in Review
7 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Fidelity Disruptive Medicine ETF (FMED) for Q2 2025, worth a combined $34.6M — up 11% from $31.1M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new FMED positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.22M. The largest seller was Jane Street, cutting an estimated $1.07M.
- 7 institutional investors held Fidelity Disruptive Medicine ETF (FMED) as of Q2 2025, up from 6 in Q1 2025.
- Funds reported $34.6M of Fidelity Disruptive Medicine ETF stock for Q2 2025, up 11% quarter-over-quarter.
- 1 fund opened new Fidelity Disruptive Medicine ETF positions in Q2 2025 and 0 closed out, a net change of +1 holder.
- The largest Fidelity Disruptive Medicine ETF buyer in Q2 2025 was Fidelity Investments, an estimated $2.22M added.
- The largest Fidelity Disruptive Medicine ETF seller in Q2 2025 was Jane Street, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2025.